Galapagos (NL:GLPG)
:GLPG
GLPG Stock Chart & Stats
€24.52
-€0.26(-1.07%)
At close: 4:00 PM EST
€24.52
-€0.26(-1.07%)
Day’s Range― - ―
52-Week Range€20.70 - €32.74
Previous CloseN/A
Volume88.54K
Average Volume (3M)132.01K
Market Cap
€1.62B
Enterprise Value€1.54B
Total Cash (Recent Filing)€3.00B
Total Debt (Recent Filing)€12.10M
Price to Earnings (P/E)5.7
Beta0.75
Next Earnings
May 06, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.87
Shares Outstanding65,897,070
10 Day Avg. Volume76,560
30 Day Avg. Volume132,014
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.85Price Target Upside5.42% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)-2.08
Revenue Forecast (FY)€81.19M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and multibillion equity provide durable financial flexibility for a biotech: it lowers refinancing and solvency risk, supports multi-year R&D funding or selective M&A, and gives management optionality to fund programs without immediate capital markets dependence.
Revenue And Profitability ReboundA pronounced revenue and earnings rebound demonstrates commercial validation or successful partnership milestones. Sustained higher revenue and improved EBIT expand operating leverage, support reinvestment in pipeline, and show the company can translate R&D into repeatable commercial economics over the medium term.
Partner-based Business ModelA collaboration/licensing model provides structural non-dilutive funding via upfronts, R&D reimbursements, milestones and royalties. This long-term model lets Galapagos focus on discovery while leveraging partners' commercial reach, reducing solo commercialization risk and enabling scalable program funding.
Bears Say
Negative Operating And Free Cash FlowPersistent negative OCF and FCF mean the business is not yet self-funding long term. That increases reliance on cash reserves or external financing, raising dilution or refinancing risk and limiting the firm's ability to organically fund pipeline expansion or weather development setbacks over the next 2-6 months and beyond.
Reliance On Non-recurring RevenueDependence on upfronts, milestones and one-off payments makes revenue lumpy and less predictable. This structural volatility complicates long-term planning, can overstate sustainable earnings in strong years, and raises execution risk if future milestone timing or partner success falters.
Declining Total AssetsA shrinking asset base may reflect reduced capital investment, asset sales, or run-off of prior investments. Even with strong equity, declining assets can limit operational capacity or signaling lower reinvestment in growth and warrants monitoring for implications on long-term R&D throughput and commercial scalability.
Galapagos News
GLPG FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest stock price was €20.70 and its highest was €32.74 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is €1.62B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is May 06, 2026 which is in 26 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Feb 23, 2026. The company reported €11.87 earnings per share for the quarter, beating the consensus estimate of -€0.11 by €11.98.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Undervalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.82.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of €11.87 in its last earnings report, beating expectations of -€0.11. Following the earnings report the stock price went up 4.085%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in NL:GLPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
GLPG Stock 12 Month Forecast
Average Price Target
€25.85
▲(5.42% Upside)
Technical Analysis
Options Prices
Currently, No data available
---